NovoCure Cash Flow Statement
NASDAQ: NVCRHealth CareMedical/Dental InstrumentsUSD
14.58+0.36 (+2.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NovoCure free cash flow
In fiscal 2025, NovoCure generated -$49.0 million of operating cash flow and spent $26.6 million on capital expenditures. That left free cash flow of -$75.7 million, a free-cash-flow margin of -11.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
NovoCure cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -136.23M | -168.63M | -207.04M | -92.53M | -58.35M | 19.81M | -7.23M | -63.56M | -61.66M | -131.84M |
| Net Income growth (YoY) | — | — | — | — | -394.58% | — | — | — | — | — |
| Depreciation & Amortization | 14.65M | 11.23M | 10.97M | 10.62M | 10.25M | 9.15M | 8.46M | 9.01M | 7.68M | 5.65M |
| Stock-Based Compensation | 104.83M | 160.03M | 115.61M | 106.95M | 94.90M | 75.72M | 52.42M | 39.85M | 27.12M | 22.14M |
| Change in Working Capital | 13.29M | 21.67M | 5.95M | 12.46M | 35.53M | -7.82M | -20.77M | 2.86M | -4.42M | -16.69M |
| Operating Cash Flow | -49.03M | -26.37M | -73.34M | 30.79M | 82.76M | 99.15M | 26.62M | -1.86M | -33.13M | -107.59M |
| Capital Expenditures | -26.65M | -42.85M | -27.09M | -21.36M | -24.17M | -14.97M | -10.48M | -6.71M | -7.37M | -5.67M |
| Investing Cash Flow | 437.28M | -140.24M | 184.15M | -139.96M | -144.83M | -472.85M | -51.67M | -5.49M | 8.63M | 13.00M |
| Dividends Paid | — | — | — | — | — | — | — | — | 0 | 0 |
| Debt Issued | 99.98M | 96.92M | 0 | 0 | — | 558.44M | 0 | 149.15M | 19.00K | 72.89M |
| Debt Repaid | -560.95M | -12.91M | -10.00K | -28.00K | -26.00K | -150.03M | -31.00K | -100.08M | -76.00K | — |
| Financing Cash Flow | -451.34M | 90.31M | 15.79M | 15.49M | 25.70M | 440.21M | 61.68M | 69.37M | 5.17M | 75.12M |
| Net Change in Cash | -62.70M | -76.47M | 126.73M | -93.78M | -36.56M | 66.76M | 36.66M | 62.04M | -19.33M | -19.64M |
| Free Cash Flow | -75.68M | -69.22M | -100.43M | 9.43M | 58.59M | 84.18M | 16.14M | -8.58M | -40.50M | -113.27M |
This table shows 10 annual periods of NovoCure's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NVCR's reporting calendar. What is a cash flow statement?